U.S. Consumer Durables Stock News

Xenon Pharmaceuticals (XENE) has quietly outperformed the market over the past month, climbing about 15% even as many biotech peers tread water and putting its late stage epilepsy pipeline back in focus for investors. See our latest analysis for Xenon Pharmaceuticals. Zooming out, the stock’s 30 day share price return of about 15% and solid 90 day share price gain suggest momentum is rebuilding after a more muted 4.42% one year total shareholder return. If Xenon’s move has you rethinking your...

Walmart (WMT) just posted its Q3 2026 numbers, with revenue of about $179.5 billion and net income of roughly $6.1 billion translating to EPS of $0.77 as investors focus on how these figures feed into the retailer’s earnings momentum story. The company has seen revenue move from around $169.6 billion in Q3 2025 to $179.5 billion in Q3 2026, while trailing twelve month net income climbed from about $19.4 billion to $22.9 billion. This sets the stage for investors to parse how sustained...

CBRE Group (CBRE) is back in the spotlight after Barclays initiated coverage with an Overweight rating, just as the company doubles down on strategic growth through its Pearce Services acquisition and fresh debt financing. See our latest analysis for CBRE Group. Despite a softer 1 day and recent 7 day share price return, CBRE’s roughly 24 percent year to date share price gain and triple digit multi year total shareholder returns suggest momentum is still very much intact as these strategic...

If you are wondering whether Ares Management is still worth buying after its big multi year run, or if the easy money has already been made, this breakdown will help you consider whether the current price still stacks up to the fundamentals. The stock just closed at $163.07, up 5.5% over the last week and 6.6% over the last month, even though it is still down 8.8% year to date and 5.5% over the past year after a 153.6% 3 year and 291.3% 5 year rally. Behind those moves, investors have been...

Gorilla Technology Group (GRRR) just kicked off a new chapter for its SPAC-era investors by issuing a CVR Payment Notice that lets qualifying CVR holders claim forfeited ordinary shares now reclassified as Price Protection Shares. See our latest analysis for Gorilla Technology Group. The CVR announcement lands after a volatile spell for Gorilla, with a 10.8% 1 day share price return and 19.3% 7 day share price return contrasting sharply with a weak year to date share price return. At the same...

AnaptysBio (ANAB) just turned its long running Jemperli partnership with Tesaro and GSK into a full blown legal battle, and that tug of war over royalties and rights is exactly what the stock is now trading on. See our latest analysis for AnaptysBio. The lawsuit has lit a fire under the stock, with a 1 month share price return of 24.64% and a year to date share price return of 224.10%, signaling powerful, litigation driven momentum, even though the 1 year total shareholder return of 83.01%...

In early December 2025, Emerson and Armexa announced a collaboration to provide DeltaV automation platform users with a global suite of operational technology cybersecurity services, including assessments, network intrusion detection deployments, and OT security for capital projects aligned with ISA/IEC 62443 standards. This move highlights how Emerson is broadening its automation offering into lifecycle OT cybersecurity, aiming to simplify vendor management and strengthen resilience for...

Wondering if CenterPoint Energy at around $38.54 is still worth buying after its strong run, or if most of the upside is already priced in? You are in the right place if you are trying to separate solid value from simple momentum. The stock is down about 3.5% over the last week and roughly flat over the past month, but it is still up 22.4% year to date and 23.4% over the last year, with a 5 year gain of just over 100.2%. That mix of near term softness and long term strength is exactly what...

Celsius Holdings recently reported a past quarter with very large year-on-year revenue growth to record sales of US$721 million, expanding its energy drink market share at home and abroad through PepsiCo-backed distribution and new entries into markets such as the U.K., France, Australia and New Zealand. At the same time, the acquisitions of Alani Nu and Rockstar have increased integration complexity and costs, raising questions about whether the company can protect margins while absorbing...

NANO Nuclear Energy (NNE) just signed a feasibility study deal with BaRupOn to explore deploying multiple KRONOS MMR units, targeting up to 1 GW of nuclear power for the massive LAMP innovation hub in Liberty, Texas. See our latest analysis for NANO Nuclear Energy. The BaRupOn feasibility study lands while NANO Nuclear Energy’s share price has been volatile, with a 1 day share price return of 7.91 percent and a 30 day share price return of negative 15.87 percent, but year to date momentum...

Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026. The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types. We’ll...

Henry Schein (HSIC) just widened its footprint in preventive dentistry, securing exclusive U.S. distribution rights for vVARDIS Curodont Repair Fluoride Plus across all dental segments starting January 1, 2026. See our latest analysis for Henry Schein. The deal lands while Henry Schein’s 90 day share price return of 5.63 percent and year to date share price return of 6.99 percent point to gradually improving momentum, even though the 3 year total shareholder return of negative 9.81 percent...

If you are wondering whether Madrigal Pharmaceuticals is still worth a look after its huge run-up, or if the smart money has already moved on, this breakdown is for you. The stock has surged an eye-catching 798.5% over the last 3 years and is still up 86.8% year to date, even after a recent 2.5% dip over the past week. Those moves have been driven by growing optimism around Madrigal's lead NASH therapy, which recently gained more attention as investors reassessed the commercial potential of...

If you are wondering whether UL Solutions at around $76.74 is still worth buying after its run this year, you are not alone. This article will break down what that price actually implies about future expectations. The stock has pulled back sharply in the short term, with a 14.9% drop over the last week and an 11.8% slide over the past month, even though it is still up 54.6% year to date and 44.2% over the last year. Recently, investors have been reacting to a mix of headlines around demand...

In recent weeks, On Holding reported quarterly results that topped revenue and earnings expectations, with sales climbing 35.1% year over year and earnings per share more than doubling compared with the same period last year. This strong fundamental performance has been followed by upward revisions to earnings estimates and a top-tier Zacks Rank rating, signaling a marked shift in analyst expectations around the company’s earnings power. We’ll now examine how this earnings beat and improving...

It hasn't been the best quarter for Hess Midstream LP ( NYSE:HESM ) shareholders, since the share price has fallen 16...

Xeris Biopharma Holdings recently received a Notice of Allowance from the USPTO for a patent application covering XP-8121, its investigational once-weekly levothyroxine formulation, and earlier this month presented at the Piper Sandler 37th Annual Healthcare Conference in New York. The XP-8121 formulation patent progress strengthens Xeris’s intellectual property position in levothyroxine delivery, potentially reinforcing its efforts to address well-known limitations of oral thyroid hormone...

Grocery Outlet Holding (GO) has quietly slipped into value territory after a steep slide over the past 3 months, even as revenue and net income growth trends tell a more mixed and nuanced story. See our latest analysis for Grocery Outlet Holding. Over the past year, that weakness has added up, with a roughly 30 percent year to date share price decline and a 1 year total shareholder return of about negative 40 percent, suggesting sentiment has shifted from growth story to turnaround watch. If...

On 4 December 2025, Veritone and Armada announced a partnership to deliver a fully integrated edge-to-enterprise data fabric that ingests, analyzes, and monetizes high-volume audio, video, drone, and sensor streams in real time for public agencies and commercial content owners. A distinctive element of this deal is its focus on turning real-world media and sensor feeds into AI-ready digital tokens, reinforcing Veritone’s push to treat data as a renewable, monetizable asset class. We’ll now...

Wondering if United Natural Foods is still a bargain after its big run over the years, or if you have missed the boat? This breakdown will help you decide whether UNFI deserves a spot on your watchlist right now. Despite a recent pullback, with the stock down 8.6% over the last week and 7.6% over the last month, United Natural Foods is still up 23.6% year to date and 41.7% over the past year. This hints that sentiment has shifted meaningfully. Investors have been reacting to ongoing efforts...

Beam Therapeutics (BEAM) jumped after analysts upgraded their outlook, pointing to progress in its sickle cell disease program and smoother manufacturing, a combination that has quickly boosted market confidence in the gene editing specialist. See our latest analysis for Beam Therapeutics. The upbeat call from analysts lands on top of already strong momentum, with an 8.12% 1 day share price return feeding into a 38.46% 90 day share price return, even as the 3 year total shareholder return...

Tower Semiconductor (NasdaqGS:TSEM) is back on traders’ radar after Q3 revenue ticked higher sequentially, and management doubled down with a fresh $300 million push into RF infrastructure and silicon photonics capacity. See our latest analysis for Tower Semiconductor. The latest capacity push comes on top of a powerful rerating, with a 30 day share price return of 32.17 percent and an 82.04 percent 90 day share price return feeding into a 130.97 percent 1 year total shareholder return. This...

Lincoln Financial recently announced that Nilanjan (Neel) Adhya will become Executive Vice President and Chief AI, Data and Analytics Officer in January 2026, reporting directly to CEO Ellen Cooper and joining the Senior Management Committee. By recruiting a veteran of BlackRock and IBM to build AI and data into core capabilities, Lincoln is signaling a deeper push to modernize customer experience and operations across its insurance and retirement businesses. We’ll now explore how appointing...

Science Applications International (SAIC) opened Q3 2026 with Q2 revenue of about $1.8 billion and basic EPS of $2.72, setting the tone for another data heavy earnings season. The company has seen quarterly revenue move from $1.82 billion in Q2 2025 to $1.77 billion in Q2 2026, while EPS over that same span ranged from $1.59 to $2.72. This frames a period of shifting top line and per share results that investors will be watching closely. With trailing net profit margins now higher than a year...